Aquestive Therapeutics (AQST) Stock Forecast, Price Target & Predictions
AQST Stock Forecast
Aquestive Therapeutics stock forecast is as follows: an average price target of $9.50 (represents a 96.28% upside from AQST’s last price of $4.84) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
AQST Price Target
The average price target for Aquestive Therapeutics (AQST) is $9.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $7.00. This represents a potential 96.28% upside from AQST's last price of $4.84.
AQST Analyst Ratings
According to 4 Wall Street analysts, Aquestive Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for AQST stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Aquestive Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 25, 2024 | Thomas Flaten | Loop Capital Markets | $7.00 | $2.31 | 203.03% | 44.63% |
| Apr 11, 2024 | David Amsellem | Piper Sandler | $10.00 | $4.07 | 145.70% | 106.61% |
| Mar 18, 2024 | Raghuram Selvaraju | H.C. Wainwright | $9.00 | $5.51 | 63.34% | 85.95% |
| Mar 15, 2024 | Francois Brisebois | Oppenheimer | $12.00 | $6.09 | 97.04% | 147.93% |
The latest Aquestive Therapeutics stock forecast, released on Jun 25, 2024 by Thomas Flaten from Loop Capital Markets, set a price target of $7.00, which represents a 203.03% increase from the stock price at the time of the forecast ($2.31), and a 44.63% increase from AQST last price ($4.84).
Aquestive Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 4 |
| Avg Price Target | - | $7.00 | $9.50 |
| Last Closing Price | $4.84 | $4.84 | $4.84 |
| Upside/Downside | -100.00% | 44.63% | 96.28% |
In the current month, the average price target of Aquestive Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Aquestive Therapeutics's last price of $4.84. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 09, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jun 25, 2024 | Lake Street | Buy | Buy | Hold |
| May 09, 2024 | Alliance Global Partners | Buy | Buy | Hold |
| Mar 09, 2023 | Wedbush | - | Outperform | Upgrade |
Aquestive Therapeutics's last stock rating was published by Oppenheimer on Aug 09, 2024. The company gave AQST a "Outperform" rating, the same as its previous rate.
Aquestive Therapeutics Financial Forecast
Aquestive Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $13.00M | $13.24M | $11.13M | $10.68M | $11.46M | $13.27M | $12.27M | $11.08M | $13.29M | $15.35M | $11.12M | $7.15M | $8.26M | $21.68M | $8.77M | $16.42M | $12.42M | $11.13M | $12.64M | $13.27M |
| Avg Forecast | $15.28M | $13.94M | $12.80M | $13.06M | $13.17M | $12.62M | $12.39M | $12.26M | $11.66M | $11.51M | $11.01M | $9.94M | $10.42M | $11.00M | $10.57M | $10.13M | $9.36M | $11.01M | $9.48M | $8.97M | $6.26M | $8.72M | $8.77M | $10.07M | $15.84M | $9.97M | $9.19M | $11.59M | $8.91M |
| High Forecast | $16.47M | $15.02M | $13.79M | $14.07M | $14.20M | $13.52M | $13.35M | $13.21M | $12.36M | $12.41M | $11.87M | $10.71M | $11.23M | $11.86M | $11.36M | $10.89M | $10.06M | $11.83M | $10.18M | $9.64M | $6.73M | $9.37M | $9.42M | $10.82M | $17.02M | $10.72M | $9.87M | $12.45M | $10.70M |
| Low Forecast | $14.48M | $13.21M | $12.13M | $12.38M | $12.48M | $11.90M | $11.74M | $11.62M | $10.88M | $10.91M | $10.44M | $9.42M | $9.87M | $10.43M | $10.00M | $9.58M | $8.85M | $10.41M | $8.96M | $8.48M | $5.92M | $8.25M | $8.29M | $9.52M | $14.98M | $9.43M | $8.68M | $10.96M | $7.13M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.13% | 1.20% | 1.12% | 1.03% | 1.04% | 1.25% | 1.21% | 1.18% | 1.21% | 1.62% | 1.24% | 1.14% | 0.95% | 2.47% | 0.87% | 1.04% | 1.25% | 1.21% | 1.09% | 1.49% |
Aquestive Therapeutics's average Quarter revenue forecast for Dec 23 based on 4 analysts is $11.66M, with a low forecast of $10.88M, and a high forecast of $12.36M. AQST's average Quarter revenue forecast represents a -10.32% decrease compared to the company's last Quarter revenue of $13.00M (Sep 23).
Aquestive Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-2.38M | $-4.21M | $9.91M | $-10.65M | $-8.25M | $-12.06M | $-9.01M | $-30.69M | $-7.23M | $-5.40M | $-7.77M | $-14.54M | $-13.12M | $1.21M | $-12.87M | $-9.11M | $-15.05M | $-17.81M | $-12.05M | $-12.36M |
| Avg Forecast | $-11.44M | $-10.44M | $-9.58M | $-9.78M | $-9.86M | $-9.45M | $-9.27M | $-9.18M | $-8.73M | $-8.62M | $-8.25M | $-7.44M | $-7.80M | $-8.55M | $-7.92M | $-10.99M | $-7.01M | $-8.24M | $-7.09M | $-8.13M | $-4.69M | $-6.53M | $-6.56M | $-12.32M | $-11.86M | $-7.47M | $-6.88M | $-9.88M | $-6.96M |
| High Forecast | $-10.84M | $-9.89M | $-9.08M | $-9.27M | $-9.35M | $-8.91M | $-8.79M | $-8.70M | $-8.14M | $-8.17M | $-7.81M | $-7.05M | $-7.39M | $-6.84M | $-7.48M | $-8.79M | $-6.63M | $-7.79M | $-6.71M | $-6.51M | $-4.43M | $-6.17M | $-6.21M | $-9.86M | $-11.21M | $-7.06M | $-6.50M | $-7.91M | $-5.56M |
| Low Forecast | $-12.33M | $-11.25M | $-10.33M | $-10.54M | $-10.63M | $-10.13M | $-9.99M | $-9.89M | $-9.26M | $-9.29M | $-8.89M | $-8.02M | $-8.41M | $-10.26M | $-8.51M | $-13.19M | $-7.53M | $-8.86M | $-7.62M | $-9.76M | $-5.04M | $-7.02M | $-7.05M | $-14.79M | $-12.75M | $-8.02M | $-7.39M | $-11.86M | $-8.35M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.28% | 0.51% | -1.33% | 1.37% | 0.96% | 1.52% | 0.82% | 4.38% | 0.88% | 0.76% | 0.96% | 3.10% | 2.01% | -0.18% | 1.04% | 0.77% | 2.02% | 2.59% | 1.22% | 1.78% |
2 analysts predict AQST's average Quarter EBITDA for Jun 23 to be $-8.25M, with a high of $-7.81M and a low of $-8.89M. This is -183.22% lower than Aquestive Therapeutics's previous annual EBITDA (Mar 23) of $9.91M.
Aquestive Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | $-2.04M | $-5.79M | $19.31M | $-18.15M | $-16.22M | $-19.84M | $-16.70M | $-47.97M | $-14.55M | $-12.37M | $-14.67M | $-20.37M | $-16.55M | $-2.33M | $-16.53M | $-12.64M | $-18.41M | $-20.47M | $-14.73M | $-15.04M |
| Avg Forecast | $-11.45M | $-11.64M | $-10.91M | $-11.45M | $-11.25M | $-10.68M | $-10.45M | $-8.07M | $-7.73M | $-10.30M | $-10.61M | $-12.73M | $-20.52M | $-17.21M | $-32.55M | $-16.12M | $-42.36M | $-39.82M | $-39.70M | $-15.35M | $-45.82M | $-41.52M | $-40.30M | $-15.83M | $-35.00M | $-65.00M | $-57.58M | $-12.08M | $-8.46M |
| High Forecast | $-10.68M | $-10.85M | $-10.17M | $-10.68M | $-10.49M | $-8.01M | $-9.74M | $-7.52M | $-3.86M | $-9.60M | $-9.89M | $-11.86M | $-19.12M | $-13.77M | $-30.24M | $-12.90M | $-39.36M | $-37.00M | $-36.88M | $-12.28M | $-42.57M | $-38.57M | $-37.45M | $-12.66M | $-32.52M | $-60.39M | $-53.50M | $-9.66M | $-6.77M |
| Low Forecast | $-12.61M | $-12.81M | $-12.01M | $-12.61M | $-12.39M | $-12.46M | $-11.51M | $-8.88M | $-10.62M | $-11.34M | $-11.68M | $-14.01M | $-22.59M | $-20.65M | $-35.71M | $-19.35M | $-46.48M | $-43.68M | $-43.55M | $-18.43M | $-50.27M | $-45.55M | $-44.22M | $-18.99M | $-38.40M | $-71.31M | $-63.17M | $-14.49M | $-10.16M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.20% | 0.55% | -1.52% | 0.88% | 0.94% | 0.61% | 1.04% | 1.13% | 0.37% | 0.31% | 0.96% | 0.44% | 0.40% | 0.06% | 1.04% | 0.36% | 0.28% | 0.36% | 1.22% | 1.78% |
Aquestive Therapeutics's average Quarter net income forecast for Jun 23 is $-10.61M, with a range of $-11.68M to $-9.89M. AQST's average Quarter net income forecast represents a -154.94% decrease compared to the company's last Quarter net income of $19.31M (Mar 23).
Aquestive Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | $7.38M | $7.36M | $7.46M | $11.81M | $12.46M | $15.59M | $13.02M | $14.98M | $12.13M | $13.13M | $13.23M | $15.58M | $11.80M | $13.89M | $14.61M | $16.47M | $13.71M | $16.25M | $17.91M | $12.35M |
| Avg Forecast | $15.99M | $14.58M | $13.39M | $13.66M | $13.78M | $13.20M | $12.96M | $12.83M | $12.20M | $12.04M | $11.52M | $10.40M | $10.90M | $11.51M | $11.06M | $10.60M | $9.79M | $11.52M | $9.91M | $9.39M | $6.55M | $9.13M | $9.17M | $10.54M | $16.57M | $10.43M | $9.61M | $12.12M | $6.95M |
| High Forecast | $17.23M | $15.72M | $14.43M | $14.72M | $14.85M | $14.15M | $13.97M | $13.82M | $12.93M | $12.98M | $12.42M | $11.20M | $11.75M | $12.40M | $11.89M | $11.39M | $10.53M | $12.38M | $10.65M | $10.09M | $7.04M | $9.81M | $9.86M | $11.32M | $17.81M | $11.21M | $10.33M | $13.03M | $8.34M |
| Low Forecast | $15.15M | $13.82M | $12.69M | $12.95M | $13.06M | $12.45M | $12.28M | $12.16M | $11.38M | $11.41M | $10.92M | $9.85M | $10.33M | $10.91M | $10.46M | $10.02M | $9.26M | $10.89M | $9.37M | $8.88M | $6.19M | $8.63M | $8.67M | $9.96M | $15.67M | $9.86M | $9.09M | $11.46M | $5.56M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.61% | 0.64% | 0.72% | 1.08% | 1.08% | 1.41% | 1.23% | 1.53% | 1.05% | 1.32% | 1.41% | 2.38% | 1.29% | 1.52% | 1.39% | 0.99% | 1.31% | 1.69% | 1.48% | 1.78% |
Aquestive Therapeutics's average Quarter SG&A projection for Dec 23 is $12.20M, based on 4 Wall Street analysts, with a range of $11.38M to $12.93M. The forecast indicates a 65.17% rise compared to AQST last annual SG&A of $7.38M (Sep 23).
Aquestive Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | $-0.00 | $0.35 | $-0.37 | $-0.30 | $-0.44 | $-0.40 | $-1.19 | $-0.37 | $-0.33 | $-0.41 | $-0.60 | $-0.49 | $-0.07 | $-0.49 | $-0.48 | $-0.74 | $-0.82 | $-0.59 | $-0.64 |
| Avg Forecast | $-0.13 | $-0.13 | $-0.12 | $-0.13 | $-0.12 | $-0.12 | $-0.12 | $-0.09 | $-0.09 | $-0.11 | $-0.12 | $-0.14 | $-0.23 | $-0.29 | $-0.36 | $-0.42 | $-0.47 | $-0.44 | $-0.44 | $-0.42 | $-0.50 | $-0.46 | $-0.44 | $-0.47 | $-0.39 | $-0.71 | $-0.63 | $-0.52 | $-0.24 |
| High Forecast | $-0.12 | $-0.12 | $-0.11 | $-0.12 | $-0.12 | $-0.09 | $-0.11 | $-0.08 | $-0.04 | $-0.11 | $-0.11 | $-0.13 | $-0.21 | $-0.27 | $-0.33 | $-0.39 | $-0.43 | $-0.41 | $-0.41 | $-0.39 | $-0.47 | $-0.42 | $-0.41 | $-0.43 | $-0.36 | $-0.66 | $-0.59 | $-0.48 | $-0.19 |
| Low Forecast | $-0.14 | $-0.14 | $-0.13 | $-0.14 | $-0.14 | $-0.14 | $-0.13 | $-0.10 | $-0.12 | $-0.12 | $-0.13 | $-0.15 | $-0.25 | $-0.32 | $-0.39 | $-0.46 | $-0.51 | $-0.48 | $-0.48 | $-0.47 | $-0.55 | $-0.50 | $-0.49 | $-0.51 | $-0.42 | $-0.78 | $-0.69 | $-0.56 | $-0.29 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.00% | -2.50% | 1.64% | 1.04% | 1.23% | 0.95% | 2.55% | 0.84% | 0.76% | 0.96% | 1.19% | 1.07% | 0.16% | 1.05% | 1.25% | 1.03% | 1.29% | 1.15% | 2.67% |
According to 2 Wall Street analysts, Aquestive Therapeutics's projected average Quarter EPS for Jun 23 is $-0.12, with a low estimate of $-0.13 and a high estimate of $-0.11. This represents a -133.33% decrease compared to AQST previous annual EPS of $0.35 (Mar 23).
Aquestive Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IRWD | Ironwood Pharmaceuticals | $4.57 | $11.67 | 155.36% | Buy |
| DVAX | Dynavax | $11.17 | $24.50 | 119.34% | Buy |
| AQST | Aquestive Therapeutics | $4.84 | $9.50 | 96.28% | Buy |
| ORGO | Organogenesis | $2.81 | $5.00 | 77.94% | Buy |
| LFCR | Lifecore Biomedical | $5.18 | $8.00 | 54.44% | Buy |
| LNTH | Lantheus | $105.55 | $146.25 | 38.56% | Buy |
| AMPH | Amphastar Pharmaceuticals | $48.09 | $66.00 | 37.24% | Buy |
| ALKS | Alkermes | $27.66 | $35.50 | 28.34% | Buy |
| ANIP | ANI Pharmaceuticals | $58.51 | $67.33 | 15.07% | Buy |
| ALIM | Alimera Sciences | $5.54 | $5.75 | 3.79% | Hold |
| AGRX | Agile Therapeutics | $1.51 | $1.00 | -33.77% | Buy |
| GHSI | Guardion Health Sciences | $9.91 | $0.01 | -99.90% | Buy |
AQST Forecast FAQ
Is Aquestive Therapeutics a good buy?
Yes, according to 4 Wall Street analysts, Aquestive Therapeutics (AQST) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of AQST's total ratings.
What is AQST's price target?
Aquestive Therapeutics (AQST) average price target is $9.5 with a range of $7 to $12, implying a 96.28% from its last price of $4.84. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Aquestive Therapeutics stock go up soon?
According to Wall Street analysts' prediction for AQST stock, the company can go up by 96.28% (from the last price of $4.84 to the average price target of $9.5), up by 147.93% based on the highest stock price target, and up by 44.63% based on the lowest stock price target.
Can Aquestive Therapeutics stock reach $7?
AQST's average twelve months analyst stock price target of $9.5 supports the claim that Aquestive Therapeutics can reach $7 in the near future.
What are Aquestive Therapeutics's analysts' financial forecasts?
Aquestive Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $50.44M (high $54.29M, low $47.75M), average EBITDA is $-37.767M (high $-35.749M, low $-40.643M), average net income is $-40.456M (high $-35.761M, low $-45.241M), average SG&A $52.77M (high $56.79M, low $49.95M), and average EPS is $-0.445 (high $-0.393, low $-0.498). AQST's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $55.08M (high $59.36M, low $52.2M), average EBITDA is $-41.238M (high $-39.081M, low $-44.44M), average net income is $-45.456M (high $-42.365M, low $-50.044M), average SG&A $57.62M (high $62.1M, low $54.61M), and average EPS is $-0.5 (high $-0.466, low $-0.55).
Did the AQST's actual financial results beat the analysts' financial forecasts?
Based on Aquestive Therapeutics's last annual report (Dec 2023), the company's revenue was $50.58M, beating the average analysts forecast of $44.12M by 14.64%. Apple's EBITDA was $-15.102M, missing the average prediction of $-33.035M by -54.29%. The company's net income was $-7.87M, missing the average estimation of $-41.365M by -80.97%. Apple's SG&A was $31.75M, missing the average forecast of $46.16M by -31.22%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.455 by -99.98%. In terms of the last quarterly report (Sep 2023), Aquestive Therapeutics's revenue was $13M, beating the average analysts' forecast of $11.51M by 12.93%. The company's EBITDA was $-2.377M, missing the average prediction of $-8.62M by -72.42%. Aquestive Therapeutics's net income was $-2.035M, missing the average estimation of $-10.303M by -80.25%. The company's SG&A was $7.38M, missing the average forecast of $12.04M by -38.69%. Lastly, the company's EPS was $0, missing the average prediction of $-0.113 by -100.00%